BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25241146)

  • 1. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
    Falkenberg N; Anastasov N; Höfig I; Bashkueva K; Lindner K; Höfler H; Rosemann M; Aubele M
    Mol Oncol; 2015 Jan; 9(1):282-94. PubMed ID: 25241146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
    Ludyga N; Anastasov N; Rosemann M; Seiler J; Lohmann N; Braselmann H; Mengele K; Schmitt M; Höfler H; Aubele M
    Mol Cancer Res; 2013 Apr; 11(4):381-92. PubMed ID: 23364537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
    Ludyga N; Anastasov N; Gonzalez-Vasconcellos I; Ram M; Höfler H; Aubele M
    Mol Biosyst; 2011 May; 7(5):1603-12. PubMed ID: 21380407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues.
    Aubele M; Spears M; Ludyga N; Braselmann H; Feuchtinger A; Taylor KJ; Lindner K; Auer G; Stering K; Höfler H; Schmitt M; Bartlett JM
    Br J Cancer; 2010 Aug; 103(5):663-7. PubMed ID: 20700126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
    Ai M; Liang K; Lu Y; Qiu S; Fan Z
    Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
    Ai M; Qiu S; Lu Y; Fan Z
    Cell Signal; 2013 Sep; 25(9):1754-61. PubMed ID: 23707532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
    Castro NE; Lange CA
    Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTK6 regulates IGF-1-induced anchorage-independent survival.
    Irie HY; Shrestha Y; Selfors LM; Frye F; Iida N; Wang Z; Zou L; Yao J; Lu Y; Epstein CB; Natesan S; Richardson AL; Polyak K; Mills GB; Hahn WC; Brugge JS
    PLoS One; 2010 Jul; 5(7):e11729. PubMed ID: 20668531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
    Hanker AB; Brown BP; Meiler J; Marín A; Jayanthan HS; Ye D; Lin CC; Akamatsu H; Lee KM; Chatterjee S; Sudhan DR; Servetto A; Brewer MR; Koch JP; Sheehan JH; He J; Lalani AS; Arteaga CL
    Cancer Cell; 2021 Aug; 39(8):1099-1114.e8. PubMed ID: 34171264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
    Peng M; Ball-Kell SM; Tyner AL
    Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
    Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
    PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
    Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.
    Suh YA; Kim JH; Sung MA; Boo HJ; Yun HJ; Lee SH; Lee HJ; Min HY; Suh YG; Kim KW; Lee HY
    Cancer Lett; 2013 May; 332(1):102-9. PubMed ID: 23348700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
    Camirand A; Lu Y; Pollak M
    Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.